What is the appropriate dose of injectable vitamin K (phytonadione) for newborn prophylaxis and for rapid reversal of warfarin anticoagulation in adults?

Injectable Vitamin K Dosing

For newborn prophylaxis, administer 0.5–1 mg intramuscularly within one hour of birth; for rapid warfarin reversal in adults with major bleeding, give 5–10 mg intravenously by slow infusion over 30 minutes combined with 4-factor prothrombin complex concentrate. 1

---

Newborn Prophylaxis

The American Academy of Pediatrics recommends a single intramuscular dose of 0.5–1 mg phytonadione within one hour of birth to prevent hemorrhagic disease of the newborn. 1 This dose is highly effective for preventing early and classic vitamin K deficiency bleeding. 2

Dosing by Birth Weight

• Term infants (>1000 g): 0.5–1 mg IM is the standard dose 1, 3
• Premature infants (<1000 g): 0.3 mg/kg may be used, as plasma levels achieved with 0.5 mg are already 550–2600 times higher than adult values 3
• High-risk neonates (premature, birth asphyxia, difficult delivery, maternal anticoagulant use): The first dose must be given IM or by slow IV route, with repeated doses based on clinical status 4

Route Considerations

• Intramuscular administration is preferred over oral for newborn prophylaxis because it provides superior protection against late vitamin K deficiency bleeding 2
• Intravenous administration may be used in high-risk neonates when IM is not feasible, but must be given slowly 4

Treatment of Hemorrhagic Disease

• For active bleeding in newborns: 1 mg subcutaneously or intramuscularly 1
• Higher doses may be necessary if the mother has been receiving oral anticoagulants 1
• Response is typically seen within 2–4 hours as evidenced by shortening of prothrombin time 1

---

Adult Warfarin Reversal

Life-Threatening Bleeding or Emergency Surgery

Administer 4-factor prothrombin complex concentrate (PCC) 25–50 U/kg IV plus vitamin K 10 mg IV by slow infusion over 30 minutes, targeting INR <1.5. 5, 6 This combination provides both immediate (PCC within 5–15 minutes) and sustained (vitamin K within 4–6 hours) reversal. 5

PCC Dosing Algorithm Based on INR

• INR 2–<4: 25 U/kg IV (maximum 5,000 U) 5
• INR 4–6: 35 U/kg IV (maximum 5,000 U) 5
• INR >6: 50 U/kg IV (maximum 5,000 U) 5

Vitamin K must be co-administered with PCC because factor VII in PCC has only a 6-hour half-life, requiring vitamin K to stimulate endogenous production of vitamin K-dependent factors for sustained reversal. 5

Major Bleeding (Non-Life-Threatening)

Give 5–10 mg vitamin K intravenously by slow infusion over 30 minutes. 5, 6 Consider adding PCC if bleeding occurs at critical sites (intracranial, intraspinal, intraocular, pericardial, retroperitoneal) or if the patient is hemodynamically unstable. 5

Elevated INR Without Bleeding

INR 5.0–9.0

• Withhold warfarin for 1–2 doses and monitor INR serially 5
• Add oral vitamin K 1–2.5 mg only if high-risk bleeding factors are present: age >65 years, prior bleeding, concurrent antiplatelet therapy, renal failure, or alcohol use 5

INR >10

• Immediately stop warfarin and give oral vitamin K 2.5–5 mg 5
• Recheck INR within 24 hours 5
• If active bleeding develops, add PCC 50 U/kg IV plus vitamin K 5–10 mg IV 5

---

Administration Guidelines

Intravenous Administration

• Maximum rate: Do not exceed 1 mg per minute 1
• Dilution: May be diluted in 0.9% sodium chloride, 5% dextrose, or 5% dextrose and sodium chloride (preservative-free) 1
• Infusion time: Administer slowly over 15–30 minutes to minimize anaphylactoid reactions 5, 6
• Monitoring: Recheck INR 15–60 minutes after PCC administration, then every 6–8 hours for 24–48 hours 5

Maximum Dose Considerations

• Do not exceed 10 mg in a single dose, as higher doses can create a prothrombotic state and prevent re-warfarinization for days 5, 6
• For initial reversal: 2.5–10 mg or up to 25 mg initially; in rare instances 50 mg may be required 1
• Frequency: Determined by prothrombin time response; if INR not shortened satisfactorily in 6–8 hours, repeat the dose 1

Route Selection

• IV preferred over oral when active bleeding or rapid correction is needed—IV achieves predictable INR reduction within 4–6 hours versus 18–24 hours for oral 5
• Subcutaneous route is contraindicated for acute reversal because absorption is unpredictable 7, 8
• Oral administration is appropriate for non-emergency situations (INR 5–10 without bleeding) 5, 9

---

Safety Considerations

Anaphylactoid Reactions

• Incidence: Approximately 3 per 100,000 IV doses 5, 6
• Manifestations: Cardiac arrest, severe hypotension, bradycardia/tachycardia, dyspnea, bronchospasm 5
• Prevention: Always infuse slowly over 30 minutes; never give as IV push 5

Thrombotic Risk

• PCC use increases risk of venous and arterial thrombosis during the recovery period 5
• Thromboprophylaxis must be considered as early as possible after bleeding control is achieved 5

Special Populations

• Mechanical heart valve patients: Use caution with rapid reversal due to heightened valve thrombosis risk; consider lower vitamin K doses (1–2 mg oral) when feasible to facilitate earlier re-anticoagulation 5
• Elderly patients (>65 years): Have exaggerated INR responses and higher bleeding risk at any given INR level 5

---

Common Pitfalls to Avoid

• Do not use vitamin K routinely for INR 4.5–10 without bleeding—randomized trials show no reduction in major bleeding despite faster INR normalization 5
• Do not delay reversal while awaiting laboratory confirmation in life-threatening bleeding; immediate treatment is mandated 5
• Do not use recombinant factor VIIa as first-line therapy due to increased thromboembolic risk 5
• Do not restart warfarin until bleeding is completely controlled, the source identified and treated, and the patient is hemodynamically stable 5